Document is current

Any future updates will be listed below

Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo

Crossref DOI link: https://doi.org/10.1007/s00432-017-2436-0

Published Online: 2017-05-23

Published Print: 2017-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark